Literature DB >> 27890880

Myopericarditis in a case of anti-signal recognition particle (anti-SRP) antibody-positive myopathy.

Mariko Tanaka1, Naoki Gamou, Hirohiko Shizukawa, Emiko Tsuda, Shun Shimohama.   

Abstract

A 79 year-old female was admitted to our hospital because of high serum creatine kinase level together with proximal muscle weakness and pain on grasping. MRI revealed inflammatory changes in femoral muscles on both sides. Muscle biopsy showed size irregularity of muscle cells, and necrosis and regeneration of fibers. Study of antibodies was also consistent with the diagnostic criteria of anti-signal recognition particle (anti-SRP) antibody-positive myopathy. On admission, the patient required pericardiocentesis for the management of exudative pericarditis. Accompanying the aggravation of myositis, negative T wave in precordial leads on ECG, ventricular extrasystoles and non-sustained ventricular tachycardia were observed. These abnormalities were resolved with the improvement of myositis by immunosuppressive treatment. These observations suggest that the myopericarditis was associated with anti-SRP antibody-positive myopathy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27890880     DOI: 10.5692/clinicalneurol.cn-000916

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  2 in total

1.  Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study.

Authors:  Aleksandra Opinc; Joanna Sarnik; Olga Brzezińska; Marcin Makowski; Anna Lewandowska-Polak; Joanna Makowska
Journal:  Rheumatol Int       Date:  2020-03-28       Impact factor: 2.631

2.  Secondary cardiac involvement in anti-SRP-antibody-positive myopathy: an 87-year-old woman with heart failure symptoms as the first clinical presentation.

Authors:  Arika Hara; Ryota Amano; Hiroaki Yokote; Masahide Ijima; Satoshi Zeniya; Toshiki Uchihara; Sawako Yada; Mayumi Masumura; Hidenobu Takei; Ichizo Nishino; Shuta Toru
Journal:  BMC Neurol       Date:  2020-01-17       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.